CD4 and neoplasm: Compared with αPD-1 and No-FMT treatment, the combination of αPD-1 and Re-FMT significantly inhibited the recruitment of CD4+ T cells (especially Tregs) and enhanced the recruitment of CD8+ T cells, B cells, and neutrophils in the subcutaneous tumor model (Figure 3B).